194 related articles for article (PubMed ID: 37230101)
1. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Griesel R; Zhao Y; Simmons B; Omar Z; Wiesner L; Keene CM; Hill AM; Meintjes G; Maartens G
Lancet HIV; 2023 Jul; 10(7):e433-e441. PubMed ID: 37230101
[TBL] [Abstract][Full Text] [Related]
2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D
D2EFT Study Group
Lancet HIV; 2024 May; ():. PubMed ID: 38788744
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
[TBL] [Abstract][Full Text] [Related]
8. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
12. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
13. Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial.
Griesel R; Hill A; Meintjes G; Maartens G
Wellcome Open Res; 2021; 6():1. PubMed ID: 33954265
[TBL] [Abstract][Full Text] [Related]
14. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
15. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G; Assoumou L; de Castro N; Post FA; Curran A; Rusconi S; De Wit S; Stephan C; Raffi F; Johnson M; Masia M; Vera J; Jones B; Grove R; Fletcher C; Duffy A; Morris K; Pozniak A;
Lancet HIV; 2024 Mar; 11(3):e156-e166. PubMed ID: 38417976
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
17. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
18. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.
Avihingsanon A; Lu H; Leong CL; Hung CC; Koenig E; Kiertiburanakul S; Lee MP; Supparatpinyo K; Zhang F; Rahman S; D'Antoni ML; Wang H; Hindman JT; Martin H; Baeten JM; Li T;
Lancet HIV; 2023 Oct; 10(10):e640-e652. PubMed ID: 37494942
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
[TBL] [Abstract][Full Text] [Related]
20. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
